INTRODUCTION {#s1}
============

There are two main types of esophageal cancer, i.e., squamous cell carcinoma and adenocarcinoma \[[@R1]\]. Esophageal squamous cell carcinoma has a poor prognosis and the highest incidence occurs in Eastern Asia and Eastern and Southern Africa \[[@R1]\]. The risk factors of esophageal squamous cell carcinoma are not well characterized. While poor nutrition, low intake of fruits and vegetables and drinking hot beverages have been identified in Asian countries \[[@R1], [@R2]\], alcohol and smoking account for 90% of the cases in Western countries \[[@R1]\]. In Taiwan, the incidence of esophageal cancer is increasing steadily \[[@R3]\] and squamous cell carcinoma represents 91% of all cases in men and 76% in women \[[@R4]\]. Esophageal adenocarcinoma, more common in Western countries, is associated with obesity and gastroesophageal reflux disease \[[@R1], [@R2]\].

In patients with type 2 diabetes mellitus (T2DM), metformin reduces the risk of several types of cancer, including thyroid cancer \[[@R5]\], oral cancer \[[@R6]\], colon cancer \[[@R7]\], kidney cancer \[[@R8]\], bladder cancer \[[@R9]\], prostate cancer \[[@R10]\], breast cancer \[[@R11]\], endometrial cancer \[[@R12]\], ovarian cancer \[[@R13]\] and cervical cancer \[[@R14]\]. However, whether metformin may reduce the risk of esophageal cancer remains to be answered. Two previous studies concluded a null association. In the 1:10 case-control study using the UK-based General Practice Research Database, metformin did not significantly alter the risk in either the analysis of all patients (3819 cases and 38190 controls) or in patients with diabetes (370 cases and 3700 controls) \[[@R15]\]. While compared to those with no prior use, the adjusted odds ratio (95% confidence interval) for patients who had received metformin prescription of 1--14, 15--29 and ≥ 30 times was 0.99 (0.74--1.33), 1.01 (0.71--1.43) and 1.23 (0.92--1.65), respectively, in the analysis of all patients; and was 0.95 (0.68--1.33), 1.02 (0.69--1.50) and 1.31 (0.93--1.85), respectively, in the analysis of diabetes patients \[[@R15]\]. Another retrospective cohort study using the reimbursement database of the Taiwan\'s National Health Insurance (NHI) estimated an adjusted hazard ratio of 0.44 (95% confidence interval: 0.07--2.61) \[[@R16]\].

By using the Taiwan\'s NHI database, the present study further explored whether metformin use in patients with T2DM might reduce the risk of esophageal cancer. The tertile cutoffs of cumulative duration were used to evaluate a dose-response relationship, with the consideration of some infections, i.e., *Helicobacter pylori* (HP), hepatitis B virus (HBV), hepatitis C virus (HCV) and Epstein-Barr virus (EBV) \[[@R17]--[@R20]\]. Only patients with newly diagnosed diabetes and incident users of metformin were recruited to reduce the "prevalent user bias" \[[@R21]\]. To reduce "immortal time bias" when the outcome can not occur during the initial period of follow-up \[[@R21], [@R22]\], patients should have been prescribed antidiabetic drugs for at least two times, and those who were followed up for \< 180 days were excluded. To reduce the confounding from the differences in baseline characteristics, Cox regression models incorporated with the inverse probability of treatment weighting (IPTW) using propensity score (PS) were created \[[@R23], [@R24]\] and sensitivity analyses were conducted in a matched-pair sample.

RESULTS {#s2}
=======

There were 16216 never users and 288013 ever users of metformin in the original sample (Figure [1](#F1){ref-type="fig"}). All baseline characteristics differed significantly, except for peripheral arterial disease, pioglitazone and EBV-related diagnoses (Table [1](#T1){ref-type="table"}). Ever users were characterized by younger age, less males, higher proportions of dyslipidemia, obesity, eye disease, and tobacco abuse, lower proportions of hypertension, nephropathy, stroke, ischemic heart disease, chronic obstructive pulmonary disease, alcohol-related diagnoses, HP infection, HBV infection and HCV infection, higher proportions of use of rosiglitazone, statin, fibrate and non-steroidal anti-inflammatory drugs (NSAID), but lower proportions of using other antidiabetic medications, angiotensin converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) and aspirin. The baseline characteristics were more comparable in the matched sample and only 6 variables (i.e., age, dyslipidemia, obesity, eye disease, insulin, and sulfonylurea) differed significantly. While examining the standardized differences, 14 of the 31 variables had values \> 10% in the original sample, but none in the matched sample. Therefore, the results derived from the matched sample would be less influenced by residual confounding from the baseline characteristics.

![Flowchart showing the procedure in selecting the original sample into the study](oncotarget-08-18802-g001){#F1}

###### Baseline characteristics between metformin never users and ever users in the original sample and the propensity score matched sample

  Variable                                                                                 Original sample   Matched sample                                                                                                    
  ---------------------------------------------------------------------------------------- ----------------- ---------------- ----------- -------- --------------- -------------- -------- ------- ------- ------- ----------- -------
  **Demographic data**                                                                                                                                                                                                         
  Age (years)\*                                                                            59.14 ± 10.39     56.62 ± 10.24    \< 0.0001   −25.27   59.14 ± 10.39   59.38 ± 9.73   0.0346   3.09                                
  Sex (men)                                                                                9296              57.33            155140      53.87    \< 0.0001       −7.21          9296     57.33   9466    58.37   0.0559      1.95
  Occupation                                                                                                                                                                                                                   
  I                                                                                        6329              39.03            116167      40.33    \< 0.0001                      6329     39.03   6370    39.28   0.5632      
  II                                                                                       3234              19.94            65964       22.90                    7.51           3234     19.94   3133    19.32               −1.66
  III                                                                                      3405              21.00            56175       19.50                    −3.73          3405     21.00   3424    21.11               0.51
  IV                                                                                       3248              20.03            49707       17.26                    −7.50          3248     20.03   3289    20.28               0.60
  **Living region**                                                                                                                                                                                                            
  Taipei                                                                                   5452              33.62            97282       33.78    \< 0.0001                      5452     33.62   5407    33.34   0.4247      
  Northern                                                                                 1656              10.21            34437       11.96                    5.73           1656     10.21   1671    10.30               0.25
  Central                                                                                  2840              17.51            51313       17.82                    0.78           2840     17.51   2852    17.59               0.16
  Southern                                                                                 2807              17.31            46184       16.04                    −3.43          2807     17.31   2710    16.71               −1.37
  Kao-Ping and Eastern                                                                     3461              21.34            58797       20.41                    −2.22          3461     21.34   3576    22.05               1.90
  **Major comorbidities**                                                                                                                                                                                                      
  Hypertension                                                                             11971             73.82            198361      68.87    \< 0.0001       −11.52         11971    73.82   11972   73.83   0.9899      0.41
  Dyslipidemia                                                                             9821              60.56            197361      68.53    \< 0.0001       17.35          9821     60.56   9636    59.42   0.0360      −1.90
  Obesity                                                                                  361               2.23             13022       4.52     \< 0.0001       12.78          361      2.23    308     1.90    0.0384      −2.47
  **Diabetes-related complications**                                                                                                                                                                                           
  Nephropathy                                                                              4130              25.47            46186       16.04    \< 0.0001       −25.40         4130     25.47   4076    25.14   0.4904      −1.44
  Eye disease                                                                              1524              9.40             41631       14.45    \< 0.0001       15.68          1524     9.40    1401    8.64    0.0171      −3.08
  Stroke                                                                                   4017              24.77            54802       19.03    \< 0.0001       −14.86         4017     24.77   4089    25.22   0.3558      1.09
  Ischemic heart disease                                                                   6203              38.25            97962       34.01    \< 0.0001       −9.42          6203     38.25   6224    38.38   0.8104      0.45
  Peripheral arterial disease                                                              2512              15.49            45880       15.93    0.1370          1.10           2512     15.49   2618    16.14   0.1067      1.65
  **Antidiabetic drugs**                                                                                                                                                                                                       
  Insulin                                                                                  1351              8.33             6096        2.12     \< 0.0001       −29.68         1351     8.33    1008    6.22    \< 0.0001   −9.60
  Sulfonylurea                                                                             11786             72.68            189783      65.89    \< 0.0001       −11.24         11786    72.68   12290   75.79   \< 0.0001   8.16
  Meglitinide                                                                              1339              8.26             10346       3.59     \< 0.0001       −21.18         1339     8.26    1257    7.75    0.0934      −1.69
  Acarbose                                                                                 1831              11.29            14526       5.04     \< 0.0001       −22.55         1831     11.29   1850    11.41   0.7394      −0.60
  Rosiglitazone                                                                            480               2.96             12955       4.50     \< 0.0001       8.50           480      2.96    475     2.93    0.8695      −0.48
  Pioglitazone                                                                             401               2.47             7015        2.44     0.7650          0.36           401      2.47    421     2.60    0.4798      0.35
  **Potential risk factors of cancer**                                                                                                                                                                                         
  COPD                                                                                     6504              40.11            110748      38.45    \< 0.0001       −3.89          6504     40.11   6439    39.71   0.4611      −0.67
  Tobacco abuse                                                                            262               1.62             5916        2.05     0.0001          3.37           262      1.62    268     1.65    0.7927      0.31
  Alcohol-related diagnoses                                                                1036              6.39             15452       5.37     \< 0.0001       −4.88          1036     6.39    1026    6.33    0.8200      −0.55
  History of HP infection                                                                  3650              22.51            54092       18.78    \< 0.0001       −10.16         3650     22.51   3637    22.43   0.8627      −0.23
  EBV-related diagnoses                                                                    95                0.59             1756        0.61     0.7039          0.27           95       0.59    88      0.54    0.6038      −0.45
  HBV infection                                                                            339               2.09             4681        1.63     \< 0.0001       −3.90          339      2.09    334     2.06    0.8456      −0.24
  HCV infection                                                                            720               4.44             9396        3.26     \< 0.0001       −6.61          720      4.44    701     4.32    0.6062      −0.59
  **Medications that are commonly used in diabetes patients and may affect cancer risk**                                                                                                                                       
  ACEI/ARB                                                                                 9591              59.15            163631      56.81    \< 0.0001       −5.24          9591     59.15   9584    59.10   0.9370      0.01
  Calcium channel blocker                                                                  9024              55.65            141412      49.10    \< 0.0001       −13.83         9024     55.65   9115    56.21   0.3088      1.23
  Statin                                                                                   6419              39.58            127142      44.14    \< 0.0001       9.48           6419     39.58   6313    38.93   0.2281      −1.17
  Fibrate                                                                                  4427              27.30            92699       32.19    \< 0.0001       10.97          4427     27.30   4287    26.44   0.0795      −1.74
  Aspirin                                                                                  7645              47.14            133306      46.28    0.0326          −2.12          7645     47.14   7572    46.69   0.4166      −0.69
  NSAID                                                                                    16133             99.49            287004      99.65    0.0008          2.71           16133    99.49   16129   99.46   0.7584      −0.08

\* Age is expressed as mean ± standard deviation

SD: standardized difference, COPD: chronic obstructive pulmonary disease, HP: *Helicobacter pylori*, EBV: Epstein-Barr virus, HBV: hepatitis B virus, HCV: hepatitis C virus, ACEI/ARB: angiotensin converting enzyme inhibitor/angiotensin receptor blocker, NSAID: non-steroidal anti-inflammatory drugs (excluding aspirin)

Table [2](#T2){ref-type="table"} shows the incidences and hazard ratios by metformin exposure. The respective number of incident esophageal cancer in ever users and never users in the original sample was 344 and 37, with respective incidence of 25.03 and 50.87 per 100,000 person-years. There was a trend of decreasing incidence with longer cumulative duration. The overall hazard ratios showed a significantly lower risk associated with metformin in either the original sample or the matched sample. When analyzed by the tertiles of cumulative duration, a reduced risk was observed mainly for the second and third tertiles, or after a cumulative duration of approximately 2 years.

###### Incidences of esophageal cancer and hazard ratios by metformin exposure

  Metformin use                                                   n     N        Person-years   Incidence rate(per 100,000 person-years)   HR      95% CI           *P* value
  --------------------------------------------------------------- ----- -------- -------------- ------------------------------------------ ------- ---------------- -----------
  **I. Original sample**                                                                                                                                            
  Never users                                                     37    16216    72733.53       50.87                                      1.000                    
  Ever users                                                      344   288013   1374345.55     25.03                                      0.487   (0.347--0.684)   \< 0.0001
  Tertiles of cumulative duration of metformin therapy (months)                                                                                                     
  Never users                                                     37    16216    72733.53       50.87                                      1.000                    
  \< 21.47                                                        210   95183    344813.60      60.90                                      1.184   (0.834--1.680)   0.3455
  21.47--46.00                                                    99    94864    472599.13      20.95                                      0.403   (0.276--0.588)   \< 0.0001
  \> 46.00                                                        35    97966    556932.83      6.28                                       0.113   (0.071--0.179)   \< 0.0001
  **II. Matched sample**                                                                                                                                            
  Never users                                                     37    16216    72733.53       50.87                                      1.000                    
  Ever users                                                      22    16216    77211.50       28.49                                      0.557   (0.329--0.944)   0.0298
  Tertiles of cumulative duration of metformin therapy (months)                                                                                                     
  Never users                                                     37    16216    72733.53       50.87                                      1.000                    
  \< 21.47                                                        15    5355     19409.77       77.28                                      1.490   (0.816--2.720)   0.1945
  21.47--45.93                                                    6     5344     26465.42       22.67                                      0.439   (0.185--1.040)   0.0614
  \> 45.93                                                        1     5517     31336.31       3.19                                       0.063   (0.009--0.460)   0.0064

HR: hazard ratio, CI: confidence interval

Table [3](#T3){ref-type="table"} shows the separate effects of some infections (i.e., HP, EBV, HBV and HCV in Model I) and the joint effect of metformin and HP infection (Model II). In Model I, only HP infection was associated with a significantly higher risk. Metformin seemed to further reduce the risk in either the patients with or without HP infection (Model II).

###### The effects of some infections and the joint effect of metformin and Helicobacter pylori infection on the risk of esophageal cancer in patients with type 2 diabetes mellitus

  Model                                                      n     N        Person-years   Incidence rate(per 100,000 person-years)   HR      95% CI           *P* value
  ---------------------------------------------------------- ----- -------- -------------- ------------------------------------------ ------- ---------------- -----------
  **Model I. Separate effect of infection**                                                                                                                    
  History of HP infection                                                                                                                                      
  No                                                         268   246487   1187121.28     22.58                                      1.000                    
  Yes                                                        113   57742    259957.80      43.47                                      1.493   (1.188--1.876)   0.0006
  History of EBV-related diagnoses                                                                                                                             
  No                                                         378   302378   1438471.85     26.28                                      1.000                    
  Yes                                                        3     1851     8607.23        34.85                                      1.280   (0.410--3.996)   0.6703
  History of HBV infection                                                                                                                                     
  No                                                         372   299209   1426369.10     26.08                                      1.000                    
  Yes                                                        9     5020     20709.98       43.46                                      1.192   (0.612--2.321)   0.6063
  History of HCV infection                                                                                                                                     
  No                                                         358   294113   1402059.96     25.53                                      1.000                    
  Yes                                                        23    10116    45019.12       51.09                                      1.373   (0.893--2.111)   0.1486
  **Model II. Joint effect of metformin and HP infection**                                                                                                     
  Metformin (−)/HP infection (+)                             12    3650     14896.45       80.56                                      1.000                    
  Metformin (+)/HP infection (+)                             101   54092    245061.34      41.21                                      0.583   (0.319--1.064)   0.0789
  Metformin (−)/HP infection (−)                             25    12566    57837.07       43.22                                      0.694   (0.347--1.388)   0.3023
  Metformin (+)/HP infection (−)                             243   233921   1129284.21     21.52                                      0.389   (0.216--0.700)   0.0017

All models were created from the original sample with adjustment for all covariates in Table [1](#T1){ref-type="table"}. Follow-up started on January 1, 2006 and ended on December 31, 2011.

HR: hazard ratio, CI: confidence interval

HP: *Helicobacter pylori*, EBV: Epstein-Barr virus, HBV: hepatitis B virus, HCV: hepatitis C virus

DISCUSSION {#s3}
==========

The findings strongly suggested that metformin significantly reduced the risk of esophageal cancer (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). Such a protective effect was consistently observed in the original sample and the matched sample, and in a dose-response pattern (Table [2](#T2){ref-type="table"}). Furthermore, HP infection was associated with an increased risk, which could be attenuated by metformin (Table [3](#T3){ref-type="table"}).

The mechanisms by which metformin reduces the risk of esophageal cancer remains to be explored. In general, metformin may exert its anticancer effect through the inhibition of tumor angiogenesis \[[@R25]\], suppressing cancer cell metabolism \[[@R26]\], activation of apoptosis and autophagy \[[@R27]\], inhibition of mammalian target of rapamycin (mTOR) \[[@R28]\], immunomodulation by increasing the number of CD8^+^ tumor-infiltrating lymphocytes \[[@R29]\], and impairing one-carbon metabolism acting like an antifolate drug \[[@R30]\]. Some *in vitro* and *in vivo* studies supported these potential mechanisms. Metformin may inhibit esophageal cancer cell proliferation, both through an activation of 5′-adenosine monophosphate-activated protein kinase followed by the inhibition of mTOR/p70S6K/pS6 signaling, and through upregulation of USP7, a positive regulator of tumor suppressor p53 \[[@R31], [@R32]\]. Additionally, metformin blocks cell cycle in G0/G1 phase in esophageal cancer cell lines by reducing the expression of cyclin D1, Cdk4 and Cdk6 \[[@R33]\], and causes autophagy and apoptosis by downregulating Stat3 (signal transducer and activator of transcription 3), resulting in a reduced expression of Bcl-2 \[[@R34]\].

Although the UK study evaluated a dose-response relationship by using three categories of prescriptions, i.e., 1--14, 15--29 and ≥ 30, it suffered from the inherent limitations of a case-control design \[[@R15]\]. The previous Taiwanese study used a retrospective cohort design, but it suffered from limitations of small numbers of esophageal cancer (6 and 21 incident cases in comparator group and metformin users, respectively) and lack of sufficient power for a dose-response analysis \[[@R16]\]. Furthermore, both studies did not adjust for HP infection, and did not consider the effects of "prevalent user bias" and "immortal time bias" \[[@R21], [@R22]\].

The present study has several strengths. First, the diagnoses were considered from all sources of claims records including outpatient visits and hospital admission. Second, most medical co-payments can be waived by the NHI in patients with cancer, and there is a low drug cost-sharing in patients with certain conditions (e.g. low-income), veterans or prescription refills for chronic disease. Therefore, the detection rate of esophageal cancer would be less biased by social classes. Third, self-reporting bias could be reduced by the use of medical records.

Some limitations should be mentioned here. First, infection with human papillomavirus is a possible risk factor of esophageal cancer \[[@R17], [@R18]\]. However, this infection was not considered in the analysis because only 8 patients with such a diagnosis could be identified from the NHI database. Second, although none of the standardized differences had a value \> 10%, the use of insulin and sulfonylurea remained statistically significant in the matched sample (Table [1](#T1){ref-type="table"}). Both have been previously linked to a significantly higher risk of cancer in our patients with T2DM \[[@R35]\] and might potentially exert a confounding. However, their impacts should be minimal because of the following reasons: analysis after excluding insulin users did not change the results (data not shown), and a higher proportion of sulfonylurea use in ever users of metformin would only underestimate the protective effect of metformin if sulfonylurea did increase the risk of esophageal cancer. Other limitations included a lack of actual measurement data for confounders such as anthropometric factors, smoking, alcohol drinking, family history, lifestyle, nutritional status, dietary pattern, history of drinking hot beverages and genetic parameters. In addition, we could not evaluate the impact of biochemical data. Another limitation is the lack of information on the pathology, grading and staging of esophageal cancer. Because squamous cell carcinoma represents 91% and 76% of all cases of esophageal cancer in men and women, respectively, in Taiwan \[[@R4]\], the findings should better be applied to squamous cell carcinoma rather than to adenocarcinoma.

In summary, this is the first study that clearly shows a risk reduction of esophageal cancer associated with metformin use, especially after 2 years of its use. Furthermore, HP infection is an important risk factor and metformin may attenuate such a risk association.

MATERIALS AND METHODS {#s4}
=====================

The NHI implemented in Taiwan since March 1995 is a compulsory and universal system of health insurance. It covers \> 99% of Taiwan residents and has contracts with \> 98% of the hospitals nationwide. The reimbursement databases are handled by the National Health Research Institutes and can be used for academic researches after proposal review and approval by an ethic review board. This study was granted with an approval number 99274.

Individuals were de-identified for the protection of privacy. Diabetes was coded 250.XX and esophageal cancer 150, based on the *International Classification of Diseases, Ninth Revision, Clinical Modification* (ICD-9-CM).

Figure [1](#F1){ref-type="fig"} shows the procedures in selecting a cohort of patients with newly diagnosed T2DM into the study (original sample). The patients should have been diagnosed as having diabetes at an onset age of 25--74 years during the period from 1999 to 2005. Patients with diabetes mellitus diagnosed during 1996--1998 were excluded to assure a first diagnosis of diabetes after 1999, and they should have been followed up in the outpatient clinic with prescription of antidiabetic drugs for 2 or more times (*n* = 423949). In Taiwan, patients with type 1 diabetes can be waived of much of the co-payment after a certified diagnosis with issuance of a so-called "Severe Morbidity Card". These patients with type 1 diabetes (*n* = 2400) were excluded because metformin is not indicated for them. Patients with missing data (*n* = 753), with a diagnosis of any cancer before entry (*n* = 44273), aged \< 25 (*n* = 21052) or ≥ 75 (*n* = 43308) years, and followed up for \< 180 days (*n* = 7941) were also excluded.

Cumulative duration (months) of metformin use was calculated and its tertiles were used for analyses. Demographic data of age, sex, occupation and living region, and factors that might be correlated with metformin use, diabetes severity or cancer risk were considered as potential confounders. The living region and occupation were classified as detailed elsewhere \[[@R7]\]. In brief, the living region was classified as Taipei, Northern, Central, Southern, and Kao-Ping/Eastern. Occupation was classified as class I (civil servants, teachers, employees of governmental or private businesses, professionals and technicians), class II (people without a specific employer, self-employed people or seamen), class III (farmers or fishermen) and class IV (low-income families supported by social welfare, or veterans).

Other confounders included 1) major comorbidities associated with diabetes mellitus: hypertension (ICD-9-CM code: 401--405), dyslipidemia (272.0--272.4) and obesity (278); 2) diabetes-related complications: nephropathy (580--589), eye disease (250.5, 362.0, 369, 366.41 and 365.44), stroke (430--438), ischemic heart disease (410--414), and peripheral arterial disease (250.7, 785.4, 443.81 and 440--448); 3) antidiabetic drugs: insulin, sulfonylurea, meglitinide, acarbose, rosiglitazone and pioglitazone; 4) potential risk factors of cancer: chronic obstructive pulmonary disease (a surrogate for smoking; 490--496), tobacco abuse (305.1, 649.0 and 989.84), alcohol-related diagnoses (291, 303, 535.3, 571.0--571.3 and 980.0), history of HP infection (defined below), diagnoses related to EBV infection (075, 710.3 and 710.4), HBV infection (070.22, 070.23, 070.32, 070.33 and V02.61) and HCV infection (070.41, 070.44, 070.51, 070.54 and V02.62); and 5) medications that are commonly used in diabetes patients and may potentially affect cancer risk: ACEI/ARB, calcium channel blocker, statin, fibrate, aspirin and NSAID (excluding aspirin). History of HP infection was defined based on one of the following two criteria: 1) having received an HP eradication therapy (detailed previously \[[@R36]\] and defined in brief as a combination use of proton pump inhibitors or H2 receptor blockers, plus clarithromycin, metronidazole or levofloxacin, plus amoxicillin or tetracycline, with or without bismuth, in the same prescription order for 7--14 days); and/or 2) HP infection diagnosis (041.86). The accuracy of disease diagnoses in the NHI database has been studied previously. Agreements between claim data and medical records are moderate to substantial, with Kappa values ranged from 0.55 to 0.86 \[[@R37]\].

Baseline characteristics between never users and ever users were compared by Student\'s t test for age and by Chi-square test for other variables.

The incidence density of esophageal cancer was calculated for never users and ever users and for the tertiles of cumulative duration of metformin therapy. The numerator was the case number of incident esophageal cancer during follow-up, and the denominator was the person-years of follow-up. Follow-up started on the first day of the use of antidiabetic drugs and ended on December 31, 2011, at the time of a new diagnosis of esophageal cancer, or on the date of death or the last reimbursement record.

The baseline characteristics shown in Table [1](#T1){ref-type="table"} were used for creating PS by logistic regression, and the treatment effect was estimated by Cox regression incorporated with IPTW using the PS \[[@R23], [@R24]\]. Hazard ratios were estimated for ever versus never users and for each tertile of cumulative duration using never users as referent.

Because the baseline characteristics were imbalanced between metformin ever and never users, additional analyses were conducted in a 1:1 PS matched-pair sample (matched sample), which was created by using the Greedy 8 → 1 digit match algorithm as recommended by Parsons \[[@R38]\]. Because the case number of metformin never users was much smaller than the ever users, the matching was based on the case number of never users. This matching method has also been applied in our previous studies \[[@R6], [@R14], [@R39]--[@R41]\].

If residual systematic differences in baseline characteristics exist, the IPTW approach may not achieve unbiased estimates \[[@R42]\]. A quantitative method based on the calculation of standardized difference has been proposed by Austin and Stuart as a test for balance diagnostics \[[@R42]\]. A value of \> 10% might indicate potential confounding from the variable \[[@R42]\]. The standardized differences for all covariates were calculated for both the original sample and the matched sample \[[@R42]\].

Traditional Cox regression models were created to evaluate the separate effect of infection of HP, EBV, HBV and HCV, and the joint effect of metformin and HP infection by categorizing the patients into 4 subgroups: 1) metformin (−)/HP infection (+), treated as the referent group; 2) metformin (+)/HP infection (+); 3) metformin (−)/HP infection (−); and 4) metformin (+)/HP infection (−). These models were created by setting an entry date on January 1, 2006, and followed patients without esophageal cancer before this date for 6 years until December 31, 2011.

Analyses were conducted using SAS statistical software, version 9.3 (SAS Institute, Cary, NC). *P* \< 0.05 was considered statistically significant.

The study is based in part on data from the National Health Insurance Research Database provided by the Bureau of National Health Insurance, Department of Health and managed by National Health Research Institutes. The interpretation and conclusions contained herein do not represent those of Bureau of National Health Insurance, Department of Health or National Health Research Institutes.
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